CL2023001433A1 - Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso - Google Patents
Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; usoInfo
- Publication number
- CL2023001433A1 CL2023001433A1 CL2023001433A CL2023001433A CL2023001433A1 CL 2023001433 A1 CL2023001433 A1 CL 2023001433A1 CL 2023001433 A CL2023001433 A CL 2023001433A CL 2023001433 A CL2023001433 A CL 2023001433A CL 2023001433 A1 CL2023001433 A1 CL 2023001433A1
- Authority
- CL
- Chile
- Prior art keywords
- mutein
- nucleic acid
- fusion protein
- human
- host cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 title abstract 5
- 108020004707 nucleic acids Proteins 0.000 title abstract 5
- 150000007523 nucleic acids Chemical class 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 abstract 6
- 210000003289 regulatory T cell Anatomy 0.000 abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 108091006020 Fc-tagged proteins Proteins 0.000 abstract 3
- 108010002350 Interleukin-2 Proteins 0.000 abstract 3
- 102000000588 Interleukin-2 Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 238000012258 culturing Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 102220579314 ARF GTPase-activating protein GIT1_L12S_mutation Human genes 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 102220351326 c.35T>A Human genes 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000055277 human IL2 Human genes 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe una muteína de interleucina-2 humana (IL-2) que comprende una secuencia de aminoácidos de SEC ID No. 1, en donde dicha muteína de IL-2 tiene al menos una mutación seleccionada de L12G, L12K, L12Q y L12S; una proteína de fusión que comprende un fragmento cristalizable de inmunoglobulina (Fc) y la muteína de IL-2 humana; un ácido nucleico aislado que codifica la muteína de IL-2 humana; un ácido nucleico aislado que codifica una porción Fc de un anticuerpo y las muteínas de IL-2 humanas; un vector de expresión que comprende el ácido nucleico aislado unido operativamente a un promotor; una célula hospedera que comprende el ácido nucleico aislado; un método para preparar una muteína de IL-2 humana que comprende cultivar la célula hospedera; un método para preparar una proteína de fusión Fc que comprende cultivar la célula hospedera; un método in vitro para aumentar la relación de células T reguladoras (Tregs) a células T no reguladoras dentro de una población de células T que comprende poner en contacto la población de células T con una cantidad eficaz de una muteína de IL-2 humana; un método in vitro para aumentar la relación de células T reguladoras (Treg) a células T no reguladoras dentro de una población de células T que comprende poner en contacto la población de células T con una cantidad eficaz de una proteína de fusión Fc; uso de la muteína de IL-2 para preparar un medicamento útil para tratar una enfermedad inflamatoria o autoinmune; uso de la proteína de fusión Fc para preparar un medicamento útil para tratar una enfermedad inflamatoria o autoinmune.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562146136P | 2015-04-10 | 2015-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001433A1 true CL2023001433A1 (es) | 2023-12-01 |
Family
ID=56098334
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002553A CL2017002553A1 (es) | 2015-04-10 | 2017-10-10 | Muteínas de interleuquina 2 para la expansión de células t regulatorias |
| CL2023001434A CL2023001434A1 (es) | 2015-04-10 | 2023-05-18 | Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso |
| CL2023001436A CL2023001436A1 (es) | 2015-04-10 | 2023-05-18 | Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso |
| CL2023001433A CL2023001433A1 (es) | 2015-04-10 | 2023-05-18 | Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002553A CL2017002553A1 (es) | 2015-04-10 | 2017-10-10 | Muteínas de interleuquina 2 para la expansión de células t regulatorias |
| CL2023001434A CL2023001434A1 (es) | 2015-04-10 | 2023-05-18 | Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso |
| CL2023001436A CL2023001436A1 (es) | 2015-04-10 | 2023-05-18 | Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso |
Country Status (7)
| Country | Link |
|---|---|
| AU (3) | AU2016246152A1 (es) |
| CA (1) | CA2982362A1 (es) |
| CL (4) | CL2017002553A1 (es) |
| IL (1) | IL254966A (es) |
| PE (1) | PE20180132A1 (es) |
| PH (1) | PH12017501856A1 (es) |
| SG (2) | SG11201708349VA (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021523741A (ja) * | 2018-05-14 | 2021-09-09 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能なインターロイキン１２ポリペプチド及びその使用方法 |
| CN114450298A (zh) * | 2019-07-26 | 2022-05-06 | 威特拉公司 | 白介素-2制剂及其用途 |
| WO2022120224A1 (en) * | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| WO2023102463A1 (en) * | 2021-12-01 | 2023-06-08 | Visterra, Inc. | Methods of using interleukin-2 agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006135112A (ru) * | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам |
| CA2749539C (en) * | 2009-01-21 | 2022-07-19 | Amgen Inc. | Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
-
2016
- 2016-05-04 AU AU2016246152A patent/AU2016246152A1/en not_active Abandoned
- 2016-05-04 CA CA2982362A patent/CA2982362A1/en active Pending
- 2016-05-04 SG SG11201708349VA patent/SG11201708349VA/en unknown
- 2016-05-04 PE PE2017002000A patent/PE20180132A1/es unknown
- 2016-05-04 SG SG10202007394VA patent/SG10202007394VA/en unknown
-
2017
- 2017-10-10 PH PH12017501856A patent/PH12017501856A1/en unknown
- 2017-10-10 IL IL254966A patent/IL254966A/en unknown
- 2017-10-10 CL CL2017002553A patent/CL2017002553A1/es unknown
-
2019
- 2019-11-15 AU AU2019264645A patent/AU2019264645B2/en active Active
-
2021
- 2021-08-12 AU AU2021215211A patent/AU2021215211A1/en not_active Abandoned
-
2023
- 2023-05-18 CL CL2023001434A patent/CL2023001434A1/es unknown
- 2023-05-18 CL CL2023001436A patent/CL2023001436A1/es unknown
- 2023-05-18 CL CL2023001433A patent/CL2023001433A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG10202007394VA (en) | 2020-09-29 |
| CL2023001434A1 (es) | 2023-12-15 |
| AU2019264645B2 (en) | 2021-08-12 |
| AU2016246152A9 (en) | 2019-07-25 |
| PE20180132A1 (es) | 2018-01-18 |
| AU2019264645A1 (en) | 2019-12-05 |
| IL254966A (en) | 2019-02-10 |
| CA2982362A1 (en) | 2016-10-13 |
| SG11201708349VA (en) | 2017-11-29 |
| PH12017501856A1 (en) | 2018-02-26 |
| CL2017002553A1 (es) | 2018-05-04 |
| AU2016246152A1 (en) | 2017-11-02 |
| CL2023001436A1 (es) | 2023-12-01 |
| AU2021215211A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001436A1 (es) | Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso | |
| AR095541A1 (es) | Muteínas de interleucina-2 (il-2) para la expansión de células t reguladoras | |
| Rodda et al. | Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity | |
| Johnston et al. | A structurally distinct TGF-β mimic from an intestinal helminth parasite potently induces regulatory T cells | |
| Locci et al. | Activin A programs the differentiation of human TFH cells | |
| EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
| AR111207A1 (es) | Anticuerpos anti-lag3 | |
| EA201992765A1 (ru) | Белки на основе антител с привитым цитокином и способы их применения в лечении рака | |
| SA517380842B1 (ar) | بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام | |
| WO2016164937A3 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
| CO2017011487A2 (es) | Muteínas de interleuquina 2 para la expansión de células t regulatorias | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| BR0306979A (pt) | Polipeptìdeo isolado, proteìna de fusão, molécula isolada de polinucleotìdeo, vetor de expressão, célula cultivada, anticorpo ou fragmento de anticorpo, e, métodos para produzir uma proteìna, para produzir um anticorpo, para estimular uma resposta imune em um mamìfero, para expandir células hematopoiéticas e progenitores de células hematopoiéticas, para detectar a presença de rna zcytor17lig e de zcytor17lig em uma amostra biológica, para matar cérlulas cancerìgenas, para inibir a proliferação induzida por zcytor17lig ou diferenciação de células hematopoiéticas e progenitoras de células hematopoiéticas, para reduzir a inflamação induzida por zcytor17lig para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero acometido por uma doença inflamatória e para detectar inflamação em um paciente | |
| CO2019004006A2 (es) | Método para incrementar los niveles de secreción de la interleucina 2 y sus proteínas derivadas | |
| ATE500331T1 (de) | Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden | |
| AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
| BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
| BR112012018914A2 (pt) | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." | |
| CO2020009402A2 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| CL2021000883A1 (es) | Composiciones de polipéptidos estabilizados con enlace disulfuro y métodos de uso | |
| PE20180576A1 (es) | ANTICUERPOS MONOCLONALES ESPECIFICOS PARA EL ANTIGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, UTILES PARA LA DETECCION Y EL DIAGNOSTICO DE LA INFECCION CAUSADA POR VRSh | |
| BR112021025359A2 (pt) | Composições de proteína anti-vegf e métodos para a produção das mesmas | |
| PE20220706A1 (es) | Muteinas de interleucina-2 para la expansion de celulas t reguladoras | |
| Yeh et al. | Activated human valvular interstitial cells sustain interleukin-17 production to recruit neutrophils in infective endocarditis |